Showing results (131-140 of 271) with videos related to

Sort By:
Pageof 28
Scandinavian Journal of Infectious Diseases|September 18, 2013
TBscore II: refining and validating a simple clinical score for treatment monitoring of patients with pulmonary tuberculosisFrauke Rudolf, Grethe Lemvik, Ebba Abate, et al.
BMC Infectious Diseases|October 6, 2011
Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapyThomas A Rasmussen, Martin Tolstrup, Jesper Melchjorsen, et al.
Genes & Development|November 30, 2016
A noncanonical auxin-sensing mechanism is required for organ morphogenesis in ArabidopsisSara Simonini, Joyita Deb, Laila Moubayidin, et al.
AIDS (London, England)|November 24, 2015
HIV-1 transcriptional activity during frequent longitudinal sampling in aviremic patients on antiretroviral therapySteffen Leth, Rasmus Nymann, Sofie Jørgensen, et al.
The Journal of Investigative Dermatology|March 29, 2002
Differential expression of inhibitory or activating CD94/NKG2 subtypes on MART-1-reactive T cells in vitiligo versus melanoma: a case reportLars Østergaard Pedersen, Claudia S Vetter, Maria C Mingari, et al.
Sleep|April 2, 2017
Cerebrospinal Fluid Biomarkers of Neurodegeneration Are Decreased or Normal in NarcolepsyPoul Jørgen Jennum, Lars Østergaard Pedersen, Justyna Maria Czarna Bahl, et al.
Human Vaccines & Immunotherapeutics|February 2, 2013
Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activationThomas Aagaard Rasmussen, Ole Schmeltz Søgaard, Christel Brinkmann, et al.
Sexually Transmitted Infections|February 16, 2007
Home screening for sexually transmitted diseases in high-risk young women: randomised controlled trialRobert L Cook, Lars Østergaard, Sharon L Hillier, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 28, 2010
Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trialOle S Søgaard, Nicolai Lohse, Zitta B Harboe, et al.
Infection and Immunity|February 29, 2012
Timing of Toll-like receptor 9 agonist administration in pneumococcal vaccination impacts both humoral and cellular immune responses as well as nasopharyngeal colonization in miceKatrine M Jensen, Jesper Melchjorsen, Frederik Dagnaes-Hansen, et al.
Pageof 28